Study of Medication for Nonallergic Rhinitis (NAR) Based on Cluster Analysis

• Status: Unknown status
• Trial end date: 2020-03-31
• Target enrollment: 0
• Participant gender: All

Summary

Chronic rhinitis (CR) is one of the most common nasal mucosal diseases in the world. In China, about 140 million people suffer from this disease. Chronic rhinitis can lead to severe economic and social burden, as well as the potential risk of developing other chronic diseases such as asthma and chronic sinusitis. Therefore, it is of great significance to explore the classification and treatment strategies of chronic rhinitis in order to improve the health level of Chinese people.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Beijing Tongren Hospital
• Collaborators: Beijing Institute of Otolaryngology; Shanghai Johnson & Johnson Pharmaceuticals, Ltd.
• Treatments: Budesonide; Levocabastine

Criteria

Inclusion Criteria:

• Not younger than 18 years old

• Diagnosed as idiopathic rhinitis

• Signed and volunteered for the study

Exclusion Criteria:

• Comorbid airway diseases including (but not limited to) upper airway infection, chronic rhinosinusitis, nasal polyps

• Allergic to the medicines about to study

• Having used oral glucocorticoids or antihistamine agents within 30 days of the enrollment